← Back to Search

Monoclonal Antibodies

Bevacizumab for Glioblastoma

Phase 1 & 2
Waitlist Available
Led By John Boockvar, MD
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 months, and until death of any cause, up to approximately 8 years
Awards & highlights

Study Summary

This trial is testing if repeated doses of the cancer drug Bevacizumab, delivered directly to the brain through the artery, is safe and effective in treating newly diagnosed patients with the most aggressive type of brain tumor, glioblastoma multiforme.

Eligible Conditions
  • Glioblastoma
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 months, and until death of any cause, up to approximately 8 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 months, and until death of any cause, up to approximately 8 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival (OS)
Progression-free Survival (PFS)
Secondary outcome measures
Number of Adverse Events

Side effects data

From 2015 Phase 4 trial • 45 Patients • NCT02036424
22%
vitreous hemorrhage
17%
worsening of cataract
9%
posterior capsule opacification
9%
vitreous syneresis
4%
cranial nerve VI palsy
4%
bradycardia
4%
pneumonia
4%
pyelonephritis
4%
colon cancer
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bevacizumab
Ozurdex

Trial Design

1Treatment groups
Experimental Treatment
Group I: SIACI of BevacizumabExperimental Treatment1 Intervention
Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280

Find a Location

Who is running the clinical trial?

Northwell HealthLead Sponsor
456 Previous Clinical Trials
470,154 Total Patients Enrolled
16 Trials studying Glioblastoma
842 Patients Enrolled for Glioblastoma
Feinstein Institute for Medical ResearchOTHER
21 Previous Clinical Trials
5,641 Total Patients Enrolled
2 Trials studying Glioblastoma
75 Patients Enrolled for Glioblastoma
John Boockvar, MDPrincipal InvestigatorFeinstein Institute for Medical Research
13 Previous Clinical Trials
794 Total Patients Enrolled
11 Trials studying Glioblastoma
753 Patients Enrolled for Glioblastoma

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT01811498 — Phase 1 & 2
Glioblastoma Research Study Groups: SIACI of Bevacizumab
Glioblastoma Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT01811498 — Phase 1 & 2
Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01811498 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Bevacizumab a new experimental drug?

"Bevacizumab is being studied in 375 active clinical trials, with 99 of those trials in Phase 3. Many of the studies for Bevacizumab are located in Taibei, Taiwan, but there are 18908 locations operating studies for Bevacizumab globally."

Answered by AI

How many test subjects are a part of this trial?

"No, this study has completed recruitment as of the most recent update on June 20th, 2022. This trial was posted February 1st, 2013 and was last updated 534 other clinical trials for glioblastoma and 375 studies involving Bevacizumab are still recruiting patients."

Answered by AI

For what sorts of ailments is Bevacizumab most commonly prescribed?

"Bevacizumab is used to treat various cancers, including ovarian cancer and nonsquamous non-small cell lung cancer."

Answered by AI

Are we still enrolling people for this experiment?

"The clinicaltrials.gov website indicates that this study is no longer recruiting patients. Although the last update was on 6/20/2022, the trial originally posted on 2/1/2013. There are 909 other trials which are still looking for participants."

Answered by AI
~3 spots leftby Mar 2025